Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Arena Pharmaceuticals Inc. Still Down After CEO's Sale

"Week-over-week prescriptions are increasing. We're very excited about that. And we expect those prescriptions to continue to increase as, yet a larger salesforce, goes into the field in the next few weeks."

-- Arena Pharmaceuticals (NASDAQ: ARNA  ) CEO Jack Lief on CNBC, June 11.

Lief was apparently so excited that he sold 38% of his stake in the company before the July 4 holiday. Investors are clearly not happy; Arena's shares fell last week, rebounded a little, but are still down substantially from where they were before the sale was announced.

Keep in mind that CEOs sell shares for all kinds of reasons. Earlier this year, Lief exercised options he had and sold the shares immediately for a profit of more than $180,000. Perhaps Lief plans to use the $1.3 million windfall from the current sale to buy a house. Property in San Diego isn't cheap you know.

Maybe he's just diversifying; he's ridden the Arena rollercoaster down and up and down again. Sometimes the front seat can be a little intense. And it's not like he got off the ride completely; he still owns almost $2 million worth of shares.

But if Lief thought there was a chance in the near future that Arena's shares were going to get to the highs the company saw in 2012 -- north of $11 per share -- it seems safe to assume that he wouldn't sell at $5.85. The inside knowledge of the day-to-day workings of the company says something about Arena Pharmaceuticals' short-term prospect.

Shares were sold under a 10b5-1 trading plan, so while Lief authorized the sale of the large block of shares, he didn't have any control over the exact timing of the sale. There's no reason to believe Lief thinks a large share price drop is imminent.

Neither is a large price increase
Arena Pharmaceuticals' marketing partner Eisai hasn't exactly rocked the launch that started in June 2013 with sales of just $8.4 million in the first quarter of this year. It doesn't seem like a problem with Qsymia per se since VIVUS (NASDAQ: VVUS  ) has equally struggled with its launch of Qsymia, registering just $9.1 million during the first quarter. We'll know for sure when Takeda launches Orexigen's (NASDAQ: OREX  ) Contrave later this year (assuming it gets approved).

Eisai increased its marketing muscle to 600 salespeople, but a lack of marketing isn't the real problem here. The only thing that's going to cure Arena, VIVUS, and Orexigen of their woes is time. Doctors have been burned too many times by side effects that have been revealed after obesity drugs have gone on the market, so they're rightfully a little apprehensive about prescribing the new drugs willy nilly. Over time, doctors will eventually become more comfortable with the drugs from Arena, VIVUS, and Orexigen and begin prescribing them to a wider audience.

If you're going to own the obesity drug makers, you should be taking a long-term perspective. There's clearly a large potential market, but it'll likely take years for them to reach it. And I'd suggest you follow Lief's lead and not take a large position in the companies. You can always add more when sales start to pick up.

Another opportunity to get in early
There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3028184, ~/Articles/ArticleHandler.aspx, 9/5/2015 10:33:20 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Brian Orelli

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Today's Market

updated 13 hours ago Sponsored by:
DOW 16,102.38 -272.38 -1.66%
S&P 500 1,921.22 -29.91 -1.53%
NASD 4,683.92 -49.58 -1.05%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/4/2015 3:59 PM
ARNA $2.74 Down -0.01 -0.36%
Arena Pharmaceutic… CAPS Rating: **
OREX $2.64 Down -0.11 -4.00%
Orexigen Therapeut… CAPS Rating: **
VVUS $1.19 Down -0.07 -5.56%
VIVUS, Inc. CAPS Rating: **